JP2018503373A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018503373A5 JP2018503373A5 JP2017534648A JP2017534648A JP2018503373A5 JP 2018503373 A5 JP2018503373 A5 JP 2018503373A5 JP 2017534648 A JP2017534648 A JP 2017534648A JP 2017534648 A JP2017534648 A JP 2017534648A JP 2018503373 A5 JP2018503373 A5 JP 2018503373A5
- Authority
- JP
- Japan
- Prior art keywords
- expression level
- determined
- cancer
- correlates
- genes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021031306A JP7325463B2 (ja) | 2014-12-30 | 2021-03-01 | がんの予後診断及び治療のための方法及び組成物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462098055P | 2014-12-30 | 2014-12-30 | |
| US62/098,055 | 2014-12-30 | ||
| PCT/US2015/067878 WO2016109546A2 (en) | 2014-12-30 | 2015-12-29 | Methods and compositions for prognosis and treatment of cancers |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021031306A Division JP7325463B2 (ja) | 2014-12-30 | 2021-03-01 | がんの予後診断及び治療のための方法及び組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018503373A JP2018503373A (ja) | 2018-02-08 |
| JP2018503373A5 true JP2018503373A5 (https=) | 2019-01-31 |
Family
ID=55315702
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017534648A Pending JP2018503373A (ja) | 2014-12-30 | 2015-12-29 | がんの予後診断及び治療のための方法及び組成物 |
| JP2021031306A Active JP7325463B2 (ja) | 2014-12-30 | 2021-03-01 | がんの予後診断及び治療のための方法及び組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021031306A Active JP7325463B2 (ja) | 2014-12-30 | 2021-03-01 | がんの予後診断及び治療のための方法及び組成物 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US11236394B2 (https=) |
| EP (1) | EP3240908A2 (https=) |
| JP (2) | JP2018503373A (https=) |
| CN (1) | CN107208138A (https=) |
| WO (1) | WO2016109546A2 (https=) |
Families Citing this family (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI715587B (zh) | 2015-05-28 | 2021-01-11 | 美商安可美德藥物股份有限公司 | Ｔｉｇｉｔ結合劑和彼之用途 |
| US12241053B2 (en) | 2015-10-09 | 2025-03-04 | The Brigham And Women's Hospital, Inc. | Modulation of novel immune checkpoint targets |
| JP6949030B2 (ja) | 2016-01-08 | 2021-10-13 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | Ｐｄ−１軸結合アンタゴニスト及び抗ｃｅａ／抗ｃｄ３二重特異性抗体を用いたｃｅａ陽性がんの治療方法 |
| WO2018029124A1 (en) * | 2016-08-08 | 2018-02-15 | F. Hoffmann-La Roche Ag | Therapeutic and diagnostic methods for cancer |
| JP7235508B2 (ja) * | 2016-11-24 | 2023-03-08 | 第一三共株式会社 | Ｐｄ－１免疫チェックポイント阻害剤による治療に対するがんの感受性を予測する方法 |
| CN110662552A (zh) | 2016-11-30 | 2020-01-07 | 昂科梅德制药有限公司 | 包含tigit结合剂的癌症治疗方法 |
| EP3333268A1 (en) * | 2016-12-09 | 2018-06-13 | Institut Paoli Calmettes | Biomarker panel for prognosis of bladder cancer |
| WO2018122249A1 (en) * | 2016-12-28 | 2018-07-05 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting the survival time of patients suffering from a microsatellite stable colorectal cancer |
| WO2018146155A1 (en) * | 2017-02-07 | 2018-08-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Tim-3 for assessing the severity of cancer |
| CN106950371B (zh) * | 2017-02-17 | 2019-03-08 | 张灏 | Pd-l1、cdk5和ctla4中的至少一种在制备肿瘤诊断试剂盒中的用途 |
| CN110546277B (zh) | 2017-03-01 | 2024-06-11 | 豪夫迈·罗氏有限公司 | 用于癌症的诊断和治疗方法 |
| EP3879535B1 (en) | 2017-06-13 | 2024-12-11 | BostonGene Corporation | Systems and methods for identifying cancer treatments from normalized biomarker scores |
| CN111164103A (zh) | 2017-06-14 | 2020-05-15 | 西奈山伊坎医学院 | 检测和治疗对免疫疗法应答的肝细胞癌类别的方法 |
| KR102348291B1 (ko) * | 2017-06-14 | 2022-01-07 | 연세대학교 산학협력단 | 암 환자의 치료 반응성을 예측하는 방법 |
| EP3652663A4 (en) * | 2017-07-14 | 2021-04-21 | Cofactor Genomics, Inc. | NEXT GENERATION IMMUNONCOLOGICAL APPLICATIONS BY SEQUENCING |
| WO2019117132A1 (ja) * | 2017-12-12 | 2019-06-20 | 地方独立行政法人神奈川県立病院機構 | がん免疫療法の予後予測のためのバイオマーカー |
| CN112771177A (zh) * | 2018-05-21 | 2021-05-07 | 纳米线科技公司 | 分子基因标签及其使用方法 |
| CN108823309B (zh) * | 2018-06-11 | 2021-11-30 | 北京大学人民医院 | 检测kiaa0125基因表达水平的物质在辅助鉴定急性淋巴细胞白血病中的应用 |
| GB201810190D0 (en) * | 2018-06-21 | 2018-08-08 | Cancer Research Tech Ltd | Prognostic and treatment response predictive method |
| KR102753455B1 (ko) * | 2018-08-08 | 2025-01-10 | 세다르스-신나이 메디칼 센터 | 암 및 자가면역 질환을 치료하기 위한 조성물 및 방법 |
| KR102084196B1 (ko) * | 2018-08-29 | 2020-03-03 | 연세대학교 산학협력단 | 면역 항암 요법의 치료 반응에 관한 정보 제공 방법 및 이를 이용한 키트 |
| US20210338727A1 (en) * | 2018-09-13 | 2021-11-04 | Nkarta, Inc. | Natural killer cell compositions and immunotherapy methods for treating tumors |
| US12590148B2 (en) | 2018-11-26 | 2026-03-31 | Nkarta, Inc. | Methods for the simultaneous expansion of multiple immune cell types, related compositions and uses of same in cancer immunotherapy |
| WO2020117952A2 (en) * | 2018-12-05 | 2020-06-11 | Genentech, Inc. | Diagnostic methods and compositions for cancer immunotherapy |
| AU2020232691B2 (en) | 2019-03-05 | 2023-06-29 | Nkarta, Inc. | CD19-directed chimeric antigen receptors and uses thereof in immunotherapy |
| CN109880894A (zh) * | 2019-03-05 | 2019-06-14 | 杭州西合森医学检验实验室有限公司 | 基于RNAseq的肿瘤免疫微环境预测模型的构建方法 |
| JP2022527972A (ja) * | 2019-04-02 | 2022-06-07 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 前悪性病変を有する患者において癌を予測及び予防する方法 |
| EP3953712A1 (en) * | 2019-04-10 | 2022-02-16 | Universität Zürich | A method for determining the likelihood of a patient being responsive to cancer immunotherapy |
| JP2022534967A (ja) * | 2019-05-30 | 2022-08-04 | ブリストル－マイヤーズ スクイブ カンパニー | 多腫瘍遺伝子シグネチャーおよびその使用 |
| WO2020245054A1 (en) * | 2019-06-01 | 2020-12-10 | Ares Trading S.A. | Pd-1 axis binding antagonist to treat cancer with genetic mutations in specific genes |
| KR102042710B1 (ko) * | 2019-07-02 | 2019-11-08 | 의료법인 성광의료재단 | 면역체크 포인트와 관련된, 난소암 진단용 바이오마커 |
| CN110804642B (zh) * | 2019-09-10 | 2022-06-21 | 清华大学 | Gpr174免疫学功能及其用途 |
| WO2021107452A1 (ko) * | 2019-11-29 | 2021-06-03 | 의료법인 성광의료재단 | 면역 세포 치료제에 대한 치료 반응성 예측용 바이오마커 |
| US20210181200A1 (en) * | 2019-12-17 | 2021-06-17 | Women's College Hospital | Ovarian cancer biomarker and methods of using same |
| GB202007099D0 (en) | 2020-05-14 | 2020-07-01 | Kymab Ltd | Tumour biomarkers for immunotherapy |
| KR20230012559A (ko) | 2020-05-19 | 2023-01-26 | 베링거 인겔하임 인터내셔날 게엠베하 | 암 치료를 위한 결합 분자 |
| CN111500733B (zh) * | 2020-05-27 | 2022-03-08 | 中国人民解放军军事科学院军事医学研究院 | 外周血单核细胞中用于非小细胞肺癌早期诊断的分子标记物 |
| CN115916348A (zh) | 2020-06-18 | 2023-04-04 | 基因泰克公司 | 使用抗tigit抗体和pd-1轴结合拮抗剂的治疗 |
| KR102647295B1 (ko) * | 2020-09-03 | 2024-03-14 | 한국과학기술연구원 | 암 면역 치료의 효능 예측을 위한 바이오마커 및 이의 용도 |
| WO2022053065A1 (zh) * | 2020-09-14 | 2022-03-17 | 信达生物制药(苏州)有限公司 | 用于预测或评估肺癌患者的生物标志物、检测方法及应用 |
| EP4247980A4 (en) * | 2020-11-19 | 2024-10-02 | Tempus AI, Inc. | DETERMINATION OF CYTOTOXIC GENE SIGNATURE AND ASSOCIATED SYSTEMS AND METHODS FOR PREDICTING RESPONSE AND TREATMENT |
| CN112530581B (zh) * | 2020-12-03 | 2023-11-21 | 安徽医科大学第一附属医院 | 一种前列腺癌患者的免疫分子分类系统及其应用 |
| EP4026918A1 (en) | 2021-01-12 | 2022-07-13 | Koninklijke Philips N.V. | Prediction of an outcome of a colorectal cancer subject |
| CN112831562A (zh) * | 2021-01-25 | 2021-05-25 | 浙江科技学院 | 一种用于预测肝癌患者切除术后复发风险的生物标志物组合、试剂盒 |
| US20240344138A1 (en) * | 2021-03-25 | 2024-10-17 | Feng Biosciences, Inc | Targeted therapies in cancer |
| WO2022211620A1 (en) * | 2021-04-01 | 2022-10-06 | Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis | Cd4/il-2 biomarker. |
| CA3226694A1 (en) | 2021-07-15 | 2023-01-19 | Katholieke Universiteit Leuven | Biomarkers predicting response of breast cancer to immunotherapy |
| JP7480754B2 (ja) | 2021-07-19 | 2024-05-10 | トヨタ自動車株式会社 | 蓄電装置 |
| CN118871463A (zh) | 2021-07-28 | 2024-10-29 | 基因泰克公司 | 用于治疗癌症的方法和组合物 |
| TW202321308A (zh) | 2021-09-30 | 2023-06-01 | 美商建南德克公司 | 使用抗ｔｉｇｉｔ抗體、抗ｃｄ３８抗體及ｐｄ—１軸結合拮抗劑治療血液癌症的方法 |
| US20260049359A1 (en) * | 2022-05-19 | 2026-02-19 | Agendia N.V. | Prediction of response to immune therapy in breast cancer patients |
| EP4537107A2 (en) | 2022-06-07 | 2025-04-16 | Genentech, Inc. | Method for determining the efficacy of a lung cancer treatment comprising an anti-pd-l1 antagonist and an anti-tigit antagonist antibody |
| KR20240051492A (ko) * | 2022-10-13 | 2024-04-22 | 주식회사 네오셀라 | 대식세포 분화 및 분포에 따른 면역세포 치료제의 치료 반응성 예측 방법 |
| IL323044A (en) | 2023-03-06 | 2025-10-01 | Genentech Inc | Prognostic and therapeutic methods for non-small cell lung cancer |
| JPWO2024225488A1 (https=) * | 2023-04-27 | 2024-10-31 | ||
| WO2024234348A1 (en) * | 2023-05-17 | 2024-11-21 | Yanjun Wang | Biomarker for immune checkpoint blockade therapy in nsclc |
| WO2025174933A1 (en) | 2024-02-14 | 2025-08-21 | Genentech, Inc. | Methods for treatment of pancreatic cancer with anti-pd-l1 ab, anti-tigit ab, gemcitabine and nab-placlitaxel |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CU22545A1 (es) | 1994-11-18 | 1999-03-31 | Centro Inmunologia Molecular | Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico |
| US4943533A (en) | 1984-03-01 | 1990-07-24 | The Regents Of The University Of California | Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor |
| US4892538A (en) | 1987-11-17 | 1990-01-09 | Brown University Research Foundation | In vivo delivery of neurotransmitters by implanted, encapsulated cells |
| US5283187A (en) | 1987-11-17 | 1994-02-01 | Brown University Research Foundation | Cell culture-containing tubular capsule produced by co-extrusion |
| EP0491007B1 (en) | 1989-09-08 | 1996-03-13 | The Johns Hopkins University | Structural alterations of the egf receptor gene in human gliomas |
| AU661533B2 (en) | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
| EP0646178A1 (en) | 1992-06-04 | 1995-04-05 | The Regents Of The University Of California | expression cassette with regularoty regions functional in the mammmlian host |
| GB9314893D0 (en) | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Quinazoline derivatives |
| EP0659439B1 (en) | 1993-12-24 | 2001-10-24 | MERCK PATENT GmbH | Immunoconjugates |
| IL112249A (en) | 1994-01-25 | 2001-11-25 | Warner Lambert Co | Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds |
| IL112248A0 (en) | 1994-01-25 | 1995-03-30 | Warner Lambert Co | Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them |
| US5679683A (en) | 1994-01-25 | 1997-10-21 | Warner-Lambert Company | Tricyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family |
| PL179659B1 (pl) | 1994-07-21 | 2000-10-31 | Akzo Nobel Nv | Kompozycja cyklicznych nadtlenków ketonów sluzaca do modyfikowania (ko)polimerów zwlaszcza do degradacji polipropylenu PL PL PL PL PL PL PL |
| US5910486A (en) | 1994-09-06 | 1999-06-08 | Uab Research Foundation | Methods for modulating protein function in cells using, intracellular antibody homologues |
| US5804396A (en) | 1994-10-12 | 1998-09-08 | Sugen, Inc. | Assay for agents active in proliferative disorders |
| MX9707453A (es) | 1995-03-30 | 1997-12-31 | Pfizer | Derivados de quinazolina. |
| GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| GB9508565D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quiazoline derivative |
| US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
| AU6267896A (en) | 1995-06-07 | 1996-12-30 | Imclone Systems Incorporated | Antibody and antibody fragments for inhibiting the growth oftumors |
| MX9800215A (es) | 1995-07-06 | 1998-03-31 | Novartis Ag | Pirrolopirimidas y procesos para su preparacion. |
| US5760041A (en) | 1996-02-05 | 1998-06-02 | American Cyanamid Company | 4-aminoquinazoline EGFR Inhibitors |
| GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
| HU228446B1 (en) | 1996-04-12 | 2013-03-28 | Warner Lambert Co | Kinazoline derivatives as irreversible inhibitors of protein-kinase, pharmaceutical compositions containing these compounds and use thereof |
| ID19609A (id) | 1996-07-13 | 1998-07-23 | Glaxo Group Ltd | Senyawa-senyawa heterosiklik |
| ID18494A (id) | 1996-10-02 | 1998-04-16 | Novartis Ag | Turunan pirazola leburan dan proses pembuatannya |
| UA73073C2 (uk) | 1997-04-03 | 2005-06-15 | Уайт Холдінгз Корпорейшн | Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція |
| US6002008A (en) | 1997-04-03 | 1999-12-14 | American Cyanamid Company | Substituted 3-cyano quinolines |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| ATE241986T1 (de) | 1997-05-06 | 2003-06-15 | Wyeth Corp | Verwendung von chinazolin verbindungen zur behandlung von polyzystischer nierenkrankheit |
| ZA986732B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitiors of tyrosine kinases |
| ZA986729B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitors of tyrosine kinases |
| TW436485B (en) | 1997-08-01 | 2001-05-28 | American Cyanamid Co | Substituted quinazoline derivatives |
| CN1278176A (zh) | 1997-11-06 | 2000-12-27 | 美国氰胺公司 | 喹唑啉衍生物作为用于治疗结肠息肉的酪氨酸激酶抑制剂的应用 |
| WO2000031048A1 (en) | 1998-11-19 | 2000-06-02 | Warner-Lambert Company | N-[4-(3-chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamide, an irreversible inhibitor of tyrosine kinases |
| ES2666152T3 (es) * | 2009-08-13 | 2018-05-03 | The Johns Hopkins University | Métodos de modulación de la función inmunitaria con anticuerpos anti-B7-H7CR |
| GB0917457D0 (en) * | 2009-10-06 | 2009-11-18 | Glaxosmithkline Biolog Sa | Method |
| JP5892794B2 (ja) * | 2009-10-02 | 2016-03-23 | 学校法人 久留米大学 | 癌患者に対する免疫療法の治療効果および／または免疫療法後の予後の予測方法、ならびに該方法に用いる遺伝子セットおよびキット |
| WO2011094483A2 (en) * | 2010-01-29 | 2011-08-04 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Immune gene signatures in cancer |
| CA2796464C (en) | 2010-04-16 | 2021-08-03 | Immune Disease Institute, Inc. | Sustained polypeptide expression from synthetic, modified rnas and uses thereof |
| US20120258878A1 (en) * | 2010-08-04 | 2012-10-11 | Med Biogene Inc. | Prognostic gene signatures for non-small cell lung cancer |
| JP6238459B2 (ja) | 2011-08-01 | 2017-11-29 | ジェネンテック， インコーポレイテッド | Ｐｄ−１軸結合アンタゴニストとｍｅｋ阻害剤を使用する癌の治療方法 |
| EP2615181A1 (en) * | 2012-01-10 | 2013-07-17 | Universite Joseph Fourier - Grenoble 1 | Cyclon expression for the identification and control of cancer cells |
| CN113967253A (zh) * | 2012-05-15 | 2022-01-25 | 百时美施贵宝公司 | 通过破坏pd-1/pd-l1信号传输的免疫治疗 |
| LT2880180T (lt) * | 2012-08-06 | 2019-01-25 | Institut National De La Santé Et De La Recherche Médicale (Inserm) | Būdai ir rinkiniai, skirti vėžiu sergančių pacientų atrankai |
| US20150299804A1 (en) * | 2012-11-15 | 2015-10-22 | Bristol-Myers Squibb Company | Biomarkers for predicting clinical response of cancer patients to treatment with immunotherapeutic agent |
-
2015
- 2015-12-29 JP JP2017534648A patent/JP2018503373A/ja active Pending
- 2015-12-29 EP EP15832855.9A patent/EP3240908A2/en active Pending
- 2015-12-29 WO PCT/US2015/067878 patent/WO2016109546A2/en not_active Ceased
- 2015-12-29 CN CN201580070110.8A patent/CN107208138A/zh active Pending
-
2017
- 2017-05-31 US US15/609,473 patent/US11236394B2/en active Active
-
2021
- 2021-03-01 JP JP2021031306A patent/JP7325463B2/ja active Active
- 2021-12-17 US US17/554,966 patent/US12385098B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018503373A5 (https=) | ||
| Fridman et al. | Tertiary lymphoid structures and B cells: An intratumoral immunity cycle | |
| Gavrielatou et al. | Biomarkers for immunotherapy response in head and neck cancer | |
| JP7430136B2 (ja) | 疲弊したｔ細胞に関連する疾患を治療するための方法および組成物 | |
| RU2017119231A (ru) | Способы и биомаркеры для прогнозирования эффективности и оценки лечения агонистом ох40 | |
| JP6815992B2 (ja) | キメラ抗原受容体療法に対する治療応答性を予測するバイオマーカーおよびその使用 | |
| JP2017536842A5 (https=) | ||
| JP2026027390A (ja) | 腫瘍微小環境の特性を使用するキメラ受容体ｔ細胞治療 | |
| Badoual et al. | PD-1–expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer | |
| US20220332823A1 (en) | Methods of treating cancer | |
| Grenga et al. | Anti-PD-L1/TGFβR2 (M7824) fusion protein induces immunogenic modulation of human urothelial carcinoma cell lines, rendering them more susceptible to immune-mediated recognition and lysis | |
| WO2021163618A1 (en) | Method of predicting response to chimeric antigen receptor therapy | |
| JP2023508947A (ja) | 循環腫瘍ｄｎａの分析を介した分子疾患評価のための方法およびシステム | |
| WO2019036724A2 (en) | CELLULAR THERAPIES TARGETING MOLECULAR MEDIATORS ASSOCIATED WITH DISEASE, FIBROUS, INFLAMMATORY, AND AUTOIMMUNE CONDITIONS | |
| CN112805378A (zh) | 用于评估整合核酸的方法 | |
| CN113710274A (zh) | 用于预测癌症免疫疗法中的长期存活的方法及组合物 | |
| Watson et al. | Novel strategies in immune checkpoint inhibitor drug development: How far are we from the paradigm shift? | |
| Wang et al. | Cancer immunology: immune escape of tumors—expression and regulation of HLA class I molecules and its role in immunotherapies | |
| KR101968452B1 (ko) | 면역요법 효능의 임상적 상관물 | |
| KR20230124912A (ko) | 키메라 수용체 및 이의 사용 방법 | |
| Guo et al. | Transcriptome deconvolution reveals absence of cancer cell expression signature in immune checkpoint blockade response | |
| Tabrizi et al. | Integrative pharmacology: advancing development of effective immunotherapies | |
| Wagner et al. | Conserved programs and specificities of T cells targeting hematological malignancies | |
| Le et al. | TIGIT as a therapeutic target of HPV-positive head and neck squamous cell carcinomas | |
| Mestrallet | Immune response and resistance of clear cell renal cell carcinoma patients following immune checkpoint blockade |